DEFA14A: Precipio Urges Immediate Shareholder Vote to Avert Costly Meeting Adjournment

Precipio, Inc. is urgently requesting shareholders to instruct their brokers to vote immediately to ensure quorum for its annual meeting and avoid significant rescheduling costs.

Summary

• Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, is requesting shareholders to vote their shares immediately.
• The deadline for voting is June 16, 2025, by 11 p.m. Eastern Time.
• The Annual Shareholders Meeting is scheduled for June 17, 2025, at 10 a.m. Eastern Time.
• As of the press release, only approximately 42% of shares have been voted, falling short of the 50% quorum requirement.
• Failure to meet the quorum will force the company to adjourn the meeting, incurring rescheduling costs estimated to be as high as $100,000.
• The current shareholder meeting costs less than $5,000.
• Management emphasizes the need for all shareholders to vote, regardless of their stance, to avoid these unnecessary expenditures.

Sentiment

Score: 3

Explanation: The urgent request for votes due to a low quorum, coupled with the explicit mention of significant potential costs for adjournment, indicates a negative operational issue that management is struggling to resolve efficiently.

Positives

• Management is proactively communicating with shareholders to address the quorum issue and avoid additional costs.
• Successful voting will prevent an estimated $100,000 in rescheduling and administrative expenses.

Negatives

• Only 42% of shares have been voted, which is below the 50% quorum required for the Annual Shareholders Meeting.
• The company faces a potential additional cost of up to $100,000 if the meeting is adjourned due to insufficient votes.

Risks

• Failure to achieve the 50% quorum requirement for the Annual Shareholders Meeting.
• Incurring significant additional costs, potentially up to $100,000, if the meeting is adjourned and rescheduled.
• General risks and uncertainties as described in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

Precipio's mission is to address cancer misdiagnoses by developing diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which also reduce healthcare expenses. The company plans to commercialize these proprietary technologies globally to further scale its reach.

Management Comments

• "Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting."
• "Management would like to avoid these unnecessary expenditures."
• "Regardless of whether you instruct your broker to vote for or against, PLEASE VOTE TODAY BY 11 p.m. Eastern Time to ensure that the quorum requirement is met, and the costs of a rescheduled meeting are avoided."

Industry Context

Precipio operates within the healthcare biotechnology sector, specifically focusing on cancer diagnostics. This industry is characterized by continuous innovation aimed at improving diagnostic accuracy, streamlining laboratory processes, and enhancing patient outcomes, while also striving to reduce overall healthcare expenses. Precipio's emphasis on combating cancer misdiagnoses aligns with a critical and high-impact area within the diagnostic field.

Stakeholder Impact

• Shareholders are directly impacted by the urgent voting request and the potential for increased administrative costs if the meeting is adjourned, which could indirectly affect shareholder value.
• The company's operations face potential disruption and an additional financial burden if the meeting is delayed and rescheduled.

Next Steps

• Shareholders are requested to vote their shares by 11 p.m. Eastern Time on June 16, 2025.
• The Annual Shareholders Meeting is scheduled to take place on June 17, 2025, at 10 a.m. Eastern Time, provided quorum is met.

Key Dates

Recommendation

Keywords

Precipio, PRPO, cancer diagnostics, biotechnology, SEC filing, proxy statement, shareholder meeting, quorum, corporate governance, NASDAQ, healthcare, diagnostics, misdiagnosis